Description

Elicvis (apixaban) Coated Tablets 2.5 mg. №20

Ingredients

Active ingredient: Apixaban 2.5 mg per tablet.

Dosage

Dosage: The usual dose of Elicvis (apixaban) is 2.5 mg twice daily. Consult your healthcare provider for the correct dosage.

Indications

Indications: Elicvis (apixaban) is indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Contraindications

Contraindications: Do not use Elicvis (apixaban) if you have a history of allergic reactions to apixaban or any other components of the product.

Directions

Directions: Take Elicvis (apixaban) exactly as prescribed by your healthcare provider. Do not change the dose or stop taking the medication without consulting your doctor.

Scientific Evidence

Elicvis (apixaban) has been extensively studied in clinical trials. Research has shown that apixaban is effective in reducing the risk of stroke and systemic embolism in patients with atrial fibrillation. A study published in the New England Journal of Medicine demonstrated that apixaban was superior to warfarin in preventing stroke or systemic embolism with less bleeding in patients with atrial fibrillation.

Additional Information

It is important to follow your healthcare provider’s instructions carefully while taking Elicvis (apixaban). Inform your doctor about all medications, including over-the-counter drugs and supplements, that you are taking to avoid potential interactions. If you experience any unusual bleeding or bruising while on Elicvis (apixaban), contact your healthcare provider immediately.

Pharmacological Effects: Apixaban is a direct factor Xa inhibitor that works by inhibiting the activity of factor Xa, a key component in the coagulation cascade. By blocking factor Xa, apixaban prevents the formation of blood clots, reducing the risk of stroke and systemic embolism.

Comparative Effectiveness: Compared to traditional anticoagulants like warfarin, apixaban has shown to be as effective in preventing strokes with a lower risk of major bleeding events. This makes apixaban a favorable choice for many patients with atrial fibrillation.